Investing.com - Actinium Pharmaceuticals reported on Wednesday second quarter earnings that matched analysts' forecasts and revenue that fell short of expectations.
Actinium Pharmaceuticals announced earnings per share of $-0.33 on revenue of $45.00K. Analysts polled by Investing.com EPS of $-0.33 on revenue of $47.5K.
Actinium Pharmaceuticals 's are down 48% and is trading at $7.030 , still down 31.75% from its 52 week high of $10.30 set on Friday, September 24, 2021.
Actinium Pharmaceuticals follows other major Healthcare sector earnings this month
Actinium Pharmaceuticals's report follows an earnings missed by Eli Lilly on Thursday, August 4, 2022, who reported EPS of $1.25 on revenue of $6.49B, EPS of $1.7 on revenue of $6.85B.
Novo Nordisk ADR had missed expectations on Thursday, August 4, 2022 with second quarter EPS of $0.7976 on revenue of $5.62B, for EPS of $0.8198 on revenue of $5.73B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar